Several investigators have attempted to pulse DCs with tumor cell lysates (30, 31) or suppress inhibitory immune checkpoints, e.g., PD-L1/PD-L2 (32, 33) in DCs to increase the efficacy of DC-based cell therapy outcomes. This evidence concerns the gene CD274 and neoplasm.